Catalyst

Slingshot members are tracking this event:

Array Bio (ARRY) Withdraws NDA for Binimetinib (MEK162) in NRAS Mutation-Positive Melanoma

Source Link:
http://seekingalpha.com/article/4036374-array-biopharma-arry-presents-35th-annual-j-p-morgan-healthcare-conference

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ARRY
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Clinicaltrials source for the Phase 3 NEMO trial
https://www.clinical...
Additional Relevant Details PDUFA originally planned for June 30th 2017
http://seekingalpha....
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Mar 20, 2017
Occurred Source:
http://www.prnewswire.com/news-releases/array-biopharma-provides-nemo-update-300425869.html
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Binimetinib, Mek162, Pdufa, Phase 3, Nemo
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.